Puberty Blockers: Study Finds No Mental Health Benefits

A long-awaited U.S. study tracking the effects of puberty blockers on children diagnosed with gender dysphoria has been quietly released after being withheld for years. The study, originally intended to affirm the mental health benefits of early medical intervention, ultimately showed no significant improvements in depression, emotional health, or behavior after two years of treatment. According to reports, the researchers delayed publication out of concern the findings would be “weaponized” by critics of gender-affirming care.
A Landmark Study With Unexpected Results
The study, titled Mental and Emotional Health of Youth after 24 months of Gender-Affirming Medical Care Initiated with Pubertal Suppression, was led by Dr. Johanna Olson-Kennedy and her colleagues as part of the Trans Youth Care United States Study. Published on medRxiv on May 14, 2025, it is the largest U.S. effort to date to examine the psychological outcomes of youth undergoing pubertal suppression using gonadotropin-releasing hormone analogs (GnRHa).
Researchers enrolled 94 participants between the ages of 8 and 16, the majority of whom were early pubertal, non-Hispanic White, and assigned male at birth. Youth were followed for 24 months, with researchers assessing their depression symptoms, emotional health, and parent-reported behavior at six-month intervals. These results were compared over time to detect any changes attributed to the use of puberty blockers.
The Findings: No Measurable Mental Health Benefit
Despite early hopes, the study’s findings showed no significant improvement in the mental or emotional well-being of participants. Depression symptoms, emotional health, and Child Behavior Checklist (CBCL) scores remained statistically unchanged over the course of the two-year study. At no point did the scores reflect clinical improvement.
This result sharply contrasts with earlier Dutch research, which suggested that puberty blockers reduced emotional distress and improved psychosocial functioning. The U.S. study failed to replicate those findings, a development that raises important questions about the universality and reliability of earlier claims.
The study’s conclusion was sober: “GnRHas have self- and parent-reported psychological and emotional health benefits for some youth, but not uniformly.” In other words, while some individuals may experience benefit, the treatment showed no consistent or statistically significant positive effects across the broader cohort.
A Study Withheld Over Political Fears
The study was completed months before its publication but remained unpublished until now. In a report by The New York Times, researchers admitted to delaying its release due to political concerns. Dr. Olson-Kennedy expressed fears that the findings might be used by opponents of gender-affirming care to justify legislative restrictions.
The decision to withhold the study sparked concerns about scientific transparency and the politicization of medical research. In a field already fraught with ideological tensions, this case illustrates the potential dangers of suppressing inconvenient data, even when gathered using rigorous methods and transparent protocols.
Implications for Medicine and Policy
These findings come at a time of intense national debate over the role of medical transition in minors. Laws banning or restricting puberty blockers have been proposed or enacted in multiple states, while medical organizations continue to support gender-affirming interventions. The release of this study introduces new data into the debate—data that complicates the prevailing narrative that blockers provide clear and consistent mental health benefits.
It also highlights the need for continued research and rigorous standards. Treatments that involve significant physiological changes in children should rest on a robust foundation of reproducible scientific evidence. This study, while not condemning the use of puberty blockers outright, urges caution and candor in how their effects are understood and communicated.
Conclusion
The Olson-Kennedy study is a pivotal development in the ongoing discussion about puberty blockers and youth mental health. Its results challenge widely held assumptions and expose the tension between science and politics in the field of gender medicine. While some still advocate for the use of blockers as part of affirming care, this study shows that the mental health benefits are not as clear-cut or guaranteed as once believed.
At the very least, the findings call for greater transparency, better data, and open scientific discourse free from ideological pressure. When the well-being of children is at stake, honest evidence—not politics—must guide medical practice.
https://www.medrxiv.org/content/10.1101/2025.05.14.25327614v1